Docetaxel/Prednisone Plus Fractionated 177Lu- J591 Antibody for Metastatic, Castrate-resistant Prostate Cancer

Inclusion Criteria:

* Histologic diagnosis of prostate adenocarcinoma.
* Patient must have progressive metastatic prostate cancer despite adequate medical or surgical castration therapy.
* Serum testosterone \< 50 mg/ml.
* Patients who have previously received docetaxel must meet BOTH of the the following criteria:

  * reason for docetaxel discontinuation must NOT have been progression of disease while receiving drug (i.e. progression of cancer must have been AFTER docetaxel discontinuation) AND
  * All docetaxel-related toxicities must have resolved to \< grade 1 (with the exception of alopecia) and the pt must be eligible by other criteria

Exclusion Criteria:

* Use of red blood cell or platelet transfusions within 4 weeks of treatment.
* Use of hematopoietic growth factors within 4 weeks of treatment.-Prior cytotoxic chemotherapy and/or radiation therapy within 4 weeks of treatment.
* Bone scan demonstrating confluent lesions involving both axial and appendicular skeleton ("superscan").
* Prior radiation therapy encompassing \>25% of skeleton.Prior treatment with 89Strontium or 153Samarium containing compounds (e.g. Metastron®, Quadramet®).
* Platelet count \<150,000/mm3.
* Absolute neutrophil count (ANC) \<2,000/mm3.
* Hematocrit \<30 percent or Hemoglobin \< 10 g/dL.
* Abnormal coagulation profile (PT or INR, PTT) \> 1.3 x upper limit of normal (unless on therapeutic anticoagulation).
* -Serum creatinine \>2.5 mg/dL.
* AST (SGOT) \>2.5x ULN.
* Bilirubin (total) \>1.5x ULN.
* Serum calcium \>11 mg/dL.
* Active serious infection.
* Active angina pectoris or New York Heart Association Class III-IV.
* ECOG Performance Status \>2.
* Life expectancy \<6 months.
* Deep vein thrombosis and/or pulmonary embolus within 1 month of study entry.
* Other serious illness(es) which might preclude completion of this study or interfere with determination of causality of any adverse effects experienced in this study.
* Prior anti-PSMA monoclonal antibody therapy with the exception of ProstaScint®.
* Prior investigational therapy within 6 weeks of treatment.
* Known history of HIV.
* Known history of myelodysplastic syndrome or leukemia